These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17914247)

  • 1. Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury.
    Whaley-Connell A; DeMarco VG; Lastra G; Manrique C; Nistala R; Cooper SA; Westerly B; Hayden MR; Wiedmeyer C; Wei Y; Sowers JR
    Am J Nephrol; 2008; 28(1):67-75. PubMed ID: 17914247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment.
    Whaley-Connell A; Habibi J; Nistala R; Cooper SA; Karuparthi PR; Hayden MR; Rehmer N; DeMarco VG; Andresen BT; Wei Y; Ferrario C; Sowers JR
    Hypertension; 2008 Feb; 51(2):474-80. PubMed ID: 18172055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat.
    Whaley-Connell AT; Chowdhury NA; Hayden MR; Stump CS; Habibi J; Wiedmeyer CE; Gallagher PE; Tallant EA; Cooper SA; Link CD; Ferrario C; Sowers JR
    Am J Physiol Renal Physiol; 2006 Dec; 291(6):F1308-14. PubMed ID: 16788142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells.
    Whaley-Connell AT; Morris EM; Rehmer N; Yaghoubian JC; Wei Y; Hayden MR; Habibi J; Stump CS; Sowers JR
    Am J Nephrol; 2007; 27(1):15-23. PubMed ID: 17204833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A treatment with rosuvastatin induced a reduction of arterial pressure and a decrease of oxidative stress in spontaneously hypertensive rats].
    Sicard P; Lauzier B; Oudot A; Busseuil D; Collin B; Duvillard L; Moreau D; Vergely C; Rochette L
    Arch Mal Coeur Vaiss; 2005; 98(7-8):804-8. PubMed ID: 16220751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. eNOS/Hsp70 interaction on rosuvastatin cytoprotective effect in neonatal obstructive nephropathy.
    Manucha W; Kurbán F; Mazzei L; Benardón ME; Bocanegra V; Tosi MR; Vallés P
    Eur J Pharmacol; 2011 Jan; 650(2-3):487-95. PubMed ID: 20940012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion.
    Park JK; Mervaala EM; Muller DN; Menne J; Fiebeler A; Luft FC; Haller H
    J Hypertens; 2009 Mar; 27(3):599-605. PubMed ID: 19262227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rosuvastatin on capillary filtration of albumin and blood pressure in rats with streptozotocin-induced diabetes.
    Tarhzaoui K; Valensi P; Boulakia FC; Lestrade R; Albertini JP; Behar A
    Diabetes Res Clin Pract; 2008 Jun; 80(3):335-43. PubMed ID: 18406000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
    Oltman CL; Kleinschmidt TL; Davidson EP; Coppey LJ; Lund DD; Yorek MA
    Vascul Pharmacol; 2008 Jan; 48(1):47-53. PubMed ID: 18164667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation.
    Corna D; Sangalli F; Cattaneo D; Carrara F; Gaspari F; Remuzzi A; Zoja C; Benigni A; Perico N; Remuzzi G
    Am J Nephrol; 2007; 27(6):630-8. PubMed ID: 17851231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
    Blanco S; Vaquero M; Gómez-Guerrero C; López D; Egido J; Romero R
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):557-65. PubMed ID: 15831368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose.
    Piconi L; Corgnali M; Da Ros R; Assaloni R; Piliego T; Ceriello A
    J Diabetes Complications; 2008; 22(1):38-45. PubMed ID: 18191076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
    Schäfer A; Fraccarollo D; Eigenthaler M; Tas P; Firnschild A; Frantz S; Ertl G; Bauersachs J
    Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1071-7. PubMed ID: 15761193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.
    Kostapanos MS; Milionis HJ; Lagos KG; Rizos CB; Tselepis AD; Elisaf MS
    Eur J Pharmacol; 2008 Aug; 590(1-3):327-32. PubMed ID: 18585701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia.
    Ott C; Ritt M; Titze SI; Schäufele T; Schmieder RE
    J Nephrol; 2009; 22(5):675-81. PubMed ID: 19810001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice.
    Verreth W; De Keyzer D; Davey PC; Geeraert B; Mertens A; Herregods MC; Smith G; Desjardins F; Balligand JL; Holvoet P
    Br J Pharmacol; 2007 Jun; 151(3):347-55. PubMed ID: 17384667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rosuvastatin on obesity-induced cardiac oxidative stress in Wistar rats--a preliminary study.
    Ansari JA; Bhandari U; Pillai KK; Haque SE
    Indian J Exp Biol; 2012 Mar; 50(3):216-22. PubMed ID: 22439437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice.
    Desjardins F; Sekkali B; Verreth W; Pelat M; De Keyzer D; Mertens A; Smith G; Herregods MC; Holvoet P; Balligand JL
    Eur Heart J; 2008 Jan; 29(1):128-37. PubMed ID: 18063594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent effect of rosuvastatin treatment on urinary protein excretion.
    Kostapanos MS; Milionis HJ; Saougos VG; Lagos KG; Kostara C; Bairaktari ET; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2007 Dec; 12(4):292-7. PubMed ID: 18172223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal and metabolic effects of tempol in obese ZSF1 rats--distinct role for superoxide and hydrogen peroxide in diabetic renal injury.
    Rafikova O; Salah EM; Tofovic SP
    Metabolism; 2008 Oct; 57(10):1434-44. PubMed ID: 18803950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.